Bringing Reality to Drug-Eluting Stents

Circulation

Volumn 109, Issue 2, 2004, Pages 140-142

  Faxon, David P ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Drugs; Focused Perspectives; Restenosis; Stents

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ACUTE HEART INFARCTION; ANGIOPLASTY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEVICE; DRUG ELUTING STENT; DRUG MECHANISM; HUMAN; INFLAMMATION; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; PRIORITY JOURNAL; RESTENOSIS; REVIEW; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNITED STATES;

CORONARY RESTENOSIS; HUMANS; PACLITAXEL; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS; REGISTRIES; SIROLIMUS; STENTS;

EID: 1642494800     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000113457.41084.82     Document Type: Review

References (21)

1. Marx SO, Marks AR. Bench to bedside: the development of rapamycin and its application to stent restenosis. Circulation. 2001;104:852-855.
2. Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002;346:1773-1780.
3. Moses JW, Leon MB, Pompa JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1324.
4. Schofer J, Schluter M, Gershlick AH, et al. for the E-SIRIUS. Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomized controlled trial (E-SIRIUS). Lancet. 2003;362:1093-1099.
5. Schampaert E. The Canadian multicenter, randomized, double-blinded trial of the sirolimus-eluting stent in the treatment of patients with de novo coronary artery lesions (C-SIRIUS): 365-day complete follow-up. Circulation. 2003;108(suppl IV):IV-703. Abstract.
6. Ellis S, Stone GW, Pompa JJ, et al. The TAXUS IV study: final angiographic results. Circulation. 2003;108(suppl IV):IV-532. Abstract.
7. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology drug-eluting stents: part I. Circulation. 2003;107:2274-2279.
8. Sousa JE, Serruys PW, Costa MA. New frontiers in cardiology drug-eluting stents: part II. Circulation. 2003;107:2383-2389.
9. Lemos PA, Serruys PW, Sousa JE. Drug-eluting stents: cost versus clinical benefit. Circulation. 2003;107:3003-3007.
10. O'Neil WW, Leon MB. Drug-eluting stents: cost versus clinical benefit. Circulation. 2003;107:3008-3011.
11. Kereiakes DJ. Hippocrates revisited: the evidence for drug-eluting stents. Circulation. 2003;107:3012-3014.
12. Laskey WK, Williams DO, Vlachos HA, et al. Changes in the practice of percutaneous coronary intervention: a comparison of enrollment waves in the National Heart, Lung, and Blood Institute (NHLBI) Dynamic Registry. Am J Cardiol. 2001;87:964-969.
13. Lemos P, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the "real world": the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation. 2004;109:190-195.
14. Saia F, Lemos PA, Lee C, et al. Sirolimus-eluting stent implantation in ST-elevation acute myocardial infarction: a clinical and angiographic study. Circulation. 2003;108:1927-1929.
15. Degertekin M, Saia F, Lemos PA, et al. Sirolimus-eluting stents for the treatment of in-stent restenosis. Minerva Cardioangiol. 2003;51:475-484.
16. Arampatzis CA, Lemos PA, Tanabe K, et al. Effectiveness of sirolimus-eluting stent for treatment of left main coronary artery disease. Am J Cardiol. 2003;92:327-329.
17. Colombo A, Stankovic G, Orlic D, et al. Modified T-stenting technique with crushing for bifurcation lesions: immediate results and 30-day outcome. Catheter Cardiovasc Interv. 2003;60:145-151.
18. Nakamura S, Muthusamy TS, Bae J-H, et al. Impact of sirolimus-eluting stents on the outcome of patients with chronic total occlusions: multicenter registry in Asia. Circulation. 2003;108(suppl IV):IV-409. Abstract.
19. FDA Public Health Web Notification: Information for Physicians on Sub-acute Thromboses (SAT) and Hypersensitivity Reactions with Use of the Cordis CYPHER Coronary Stent. Issued October 29, 2003. Available at: http://www.fda.gov/cdrh/safety/cypher.html. Accessed December 17, 2003.
20. Abizaid A, Chan C, Kaul U, et al. "Real world" evaluation of slow-release, polymer-based, paclitaxel-eluting TAXUS stents in native coronary arteries: the WISDOM international registry. Circulation 2003;108(suppl IV):IV-534. Abstract.
21. Guagliumi G, Sousa E, Urban P, et al. Sirolimus-eluting stent in routine clinical practice: a 6-month follow-up report from the international e-CYPHER registry. Circulation. 2003;108(suppl IV):IV-534. Abstract.